Gail L.
Gail L. Brown, Woodside, CA US
Patent application number | Description | Published |
---|---|---|
20110301102 | COMPOSITIONS AND METHODS FOR TREATING MYELODYSPLASTIC SYNDROME - This invention relates to specific treatment regimens for treating myelodysplastic syndrome. | 12-08-2011 |
20110301198 | COMPOSITIONS AND METHODS FOR TREATING MYELODYSPLASTIC SYNDROME - This invention generally relates to compositions and methods for treating myelodysplastic syndrome. In one embodiment, this invention relates to methods for treating myelodysplastic syndrome with ezatiostat or a salt thereof and lenalidomide. | 12-08-2011 |
20110301199 | COMPOSITIONS AND METHODS FOR TREATING MYELODYSPLASTIC SYNDROME - This invention generally relates to compositions and methods for treating myelodysplastic syndrome. In one embodiment, this invention relates to methods for treating myelodysplastic syndrome with ezatiostat or a salt thereof in patients who have been treated with a DNA methyltransferase inhibitor by a combination of ezatiostat or a salt thereof and lenalidomide. | 12-08-2011 |
20120288554 | CANFOSFAMIDE MONOTHERAPY FOR TREATING MULTIPLE MYELOMA - Provided herein are methods for treating multiple myeloma by administering canfosfamide or a pharmaceutically acceptable salt thereof as a monotherapy, and also by administering canfosfamide or a pharmaceutically acceptable salt thereof as part of novel combination therapies further comprising one or more of bortezomib, lenalidomide, vorinostat, carfilzomib, pomalidomide, and elotuzumab. | 11-15-2012 |
20130035389 | METHODS FOR TREATING MYELODYSPLASTIC SYNDROME WITH EZATIOSTAT - This invention relates to methods, assays, devices and systems for identifying patients having a myelodysplastic syndrome for treatment with ezatiostat or a salt thereof, or evaluating the patient's response possibility to the treatment by measuring and evaluating the patient's gene expression profile. This invention also relates to methods of treating myelodysplastic syndromes. | 02-07-2013 |
20140329754 | COMPOSITIONS AND METHODS FOR TREATING MYELODYSPLASTIC SYNDROME - This invention generally relates to compositions and methods for treating myelodysplastic syndrome. In one embodiment, this invention relates to methods for treating myelodysplastic syndrome with ezatiostat or a salt thereof and lenalidomide. | 11-06-2014 |
Gail L. Jurgella, Madison, WI US
Patent application number | Description | Published |
---|---|---|
20090133137 | Method of cloning animals - The present invention relates to cloning technologies. The invention relates in part to immortalized and totipotent cells useful for cloning animals, the embryos produced from these cells using nuclear transfer techniques, animals that arise from these cells and embryos, and materials, methods, and processes for establishing such cells, embryos, and animals. | 05-21-2009 |
Gail L. Matters, Hummelstown, PA US
Patent application number | Description | Published |
---|---|---|
20110052668 | Identification and Characterization of a Specific CCK-C Receptor Antibody for Human Pancreatic Cancer and Its Use for Early Detection and Staging of Pancreatic Cancer - Human pancreatic cancer cells possess a distinct plasma membrane CCK receptor variant that can be differentiated from the classic CCK-B receptor with selective monoclonal antibodies. Use of this receptor may be helpful in early detection or treatment of patients with pancreatic cancer. | 03-03-2011 |
20110129413 | Bioconjugation of Calcium Phosphosilicate Nanoparticles For Selective Targeting of Cells In Vivo - Non-aggregating resorbable calcium phosphosilicate nanoparticles (CPNPs) are bioconjugated to targeting molecules that are specific for particular cells. The CPNPs are stable particles at normal physiological pH. Chemotherapy and imaging agents may be integrally formed with the CPNPs so that they are compartmentalized within the CPNPs. In this manner, the agents are protected from interaction with the environment at normal physiological pH. However, once the CPNPs have been taken up, at intracellular pH, the CPNPs dissolve releasing the agent. Thus, chemotherapeutic or imaging agents are delivered to specific cells and permit the treatment and/or imaging of those cells. Use of the bioconjugated CPNPs both limits the amount of systemic exposure to the agent and delivers a higher concentration of the agent to the cell. The methods and principals of bioconjugating CPNPs are taught by examples of bioconjugation of targeting molecules for breast cancer, pancreatic cancer, and leukemia. | 06-02-2011 |
Gail L. Yoss, Chesterfield, VA US
Patent application number | Description | Published |
---|---|---|
20090014020 | Smoking article with valve - A smoking article having a cylinder of smoking material, a hollow tube within the cylinder of smoking material, and a filter attached to the cylinder of smoking material. The filter includes an upstream segment containing an aerosol former, a downstream segment containing a sorbent material, and a valve positioned between the upstream segment and the downstream segment. The valve has a first position in which the valve is closed and a second position in which the valve is open and allows the passage of smoke through the filter. | 01-15-2009 |